FDA To Tackle Critical Generics Issue In Switch Paradigm Debate
This article was originally published in The Tan Sheet
Executive Summary
Commissioner Hamburg says FDA asked for input on a “new paradigm” for nonprescription drug approvals in part because pharmaceutical firms have concerns about whether potential access restrictions imposed on an innovating switch would also apply to generic versions that eventually reach the market.
You may also be interested in...
FDA Digs Deeper On “New Paradigm” To Expand Rx Switches
The questions FDA poses for a March 22-23 hearing indicate the agency is delving into greater detail than in its previous discussions of alternative routes to access pharmaceutical treatments. FDA says decisions would be made case by case, but refers to treating conditions including high cholesterol, high blood pressure, migraines and asthma.
Pharmacists See Challenges, Opportunities In Behind-The-Counter Class
Pharmacy trade groups welcome the possibility of a behind-the-counter class of drugs, but a pharmacy professor and former FDA Nonprescription Drugs Advisory Committee chairman cautions a third class could create more demand than pharmacists are able to manage
Jurors' Answers In FTC Complaint Against Prevagen Might Form A Memory Bubble For Health Claims
“No” answers in New York federal court on whether all but two of Prevagen claims were “materially misleading” could put a fork in the road of a long dispute between FTC and supplement product manufacturers and marketers.